Ashwin Shahir Selected Research

olaratumab

1/2021	Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
1/2020	Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
1/2020	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
1/2019	Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
12/2018	Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
1/2017	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
7/2016	Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ashwin Shahir Research Topics

Disease

5	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 07/2016
3	Neoplasms (Cancer) 01/2018 - 07/2009
2	Mucositis 12/2018 - 07/2016
2	Nausea 12/2018 - 07/2016
2	Fatigue 12/2018 - 01/2018
1	Infections 01/2021
1	Pinealoma (Pineoblastoma) 01/2021
1	Rhabdomyosarcoma 01/2021
1	Central Nervous System Neoplasms 01/2021
1	Cardiotoxicity 01/2021
1	Leiomyosarcoma 01/2020
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Adenocarcinoma 01/2019
1	Prostatic Neoplasms (Prostate Cancer) 01/2019
1	Ovarian Neoplasms (Ovarian Cancer) 12/2018
1	Constipation 12/2018
1	Stomatitis 01/2018
1	Tremor (Tremors) 01/2018
1	Exanthema (Rash) 01/2018
1	Disease Progression 01/2017
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017
1	Neutropenia 07/2016
1	Vomiting 07/2016
1	Febrile Neutropenia 07/2016
1	Pheochromocytoma 07/2009

Drug/Important Bio-Agent (IBA)

7	olaratumabIBA 01/2021 - 07/2016
6	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 07/2016
2	AnthracyclinesIBA 01/2021 - 07/2016
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2019 - 01/2017
1	Alanine Transaminase (SGPT)IBA 01/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2021
1	TransferasesIBA 01/2021
1	Vincristine (Oncovin)FDA LinkGeneric 01/2021
1	Dexrazoxane (Zinecard)FDA LinkGeneric 01/2021
1	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2019
1	Prednisone (Sone)FDA LinkGeneric 01/2019
1	Docetaxel (Taxotere)FDA Link 01/2019
1	PlatinumIBA 12/2018
1	liposomal doxorubicin (Doxil)FDA Link 12/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2018
1	p38 Mitogen-Activated Protein KinasesIBA 01/2018
1	Monoclonal AntibodiesIBA 07/2016
1	Growth Factor ReceptorsIBA 07/2016
1	Phentolamine (Z-Max)FDA LinkGeneric 07/2009
1	Simendan (Levosimendan)IBA 07/2009
1	Dobutamine FDA LinkGeneric 07/2009
1	IodineIBA 07/2009

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2021 - 07/2016
1	Intravenous Administration 01/2020
1	Castration 01/2019
1	Intravenous Infusions 12/2018
1	Heart-Assist Devices 07/2009